SCHEMBL6657093

SCHEMBL6657093

C1=Nc2sccc2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL169947 0.70 CES1 (0.35)
SCHEMBL4757718 0.67
SCHEMBL17948230 0.65
SCHEMBL2925217 0.65
SCHEMBL3826710 0.62
SCHEMBL4110453 0.58 NOS3 (0.36)
SCHEMBL2685546 0.57
SCHEMBL11977449 0.57
SCHEMBL11215080 0.56 PNMT (0.34)
SCHEMBL12230615 0.55 PNMT (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3239139-B1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE NINGBO COMBIREG PHARMACEUTICAL TECH CO LTD (CN) 2020-10-28 EP disclosed
EP-3239139-A1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE Shenzhen Salubris Pharmaceuticals Co., Ltd (CN) 2017-11-01 EP disclosed
EP-2612857-B1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE SHENZHEN SALUBRIS PHARM CO LTD (CN) 2017-07-26 EP disclosed
US-9085605-B2 Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2015-07-21 US disclosed
US-9085605-B2 Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2015-07-21 US disclosed
EP-2612857-A1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE Institute of Mataria Medica, Chinese Academy of Medical Sciences (CN) 2013-07-10 EP disclosed
US-20130143826-A1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2013-06-06 US disclosed
US-20130143826-A1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2013-06-06 US disclosed
WO-2011147330-A1 CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE 中国医学科学院药物研究所 (CN) 2011-12-01 WO disclosed
CN-1896078-A Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2007-01-17 CN disclosed
CN-1264846-C Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2006-07-19 CN disclosed
EP-1317459-B1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2004-04-07 EP disclosed
CN-1473163-A Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors 2004-02-04 CN disclosed
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2003-12-18 US disclosed
EP-1317459-A1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS AstraZeneca AB (SE) 2003-06-11 EP disclosed
WO-2002020530-A1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2002-03-14 WO disclosed